Non-invasive Cancer Diagnostics Market Outlook 2031
- The global non-invasive cancer diagnostics market was valued at US$ 104.8 Bn in 2021
- The global market is projected to grow at a CAGR of 7.0% from 2022 to 2031
- The global non-invasive cancer diagnostics market is anticipated to reach more than US$ 207 Bn by 2031
Non-invasive Cancer Diagnostics Market Introduction
Cancer is a disease, in which some of the body’s cells grow uncontrollably and spread to other parts. It is a group of more than 100 different diseases, which develop almost anywhere in the body. Diagnostic testing of cancer involves tests and procedures to confirm the presence of the disease, and identification of the correct tumor type, location, extent, and stage. Cancer diagnosis is performed with various methods or techniques such as physical exam, laboratory tests, imaging tests, and biopsy. Oncologists use one or more approaches to diagnose cancer. These techniques are categorized into invasive or minimally invasive and non-invasive. Invasive cancer diagnosis (painstaking cancer diagnosis) or minimally invasive cancer diagnosis techniques include laboratory test (blood test) and biopsy, while non-invasive cancer diagnosis (unintrusive cancer diagnosis) techniques comprise imaging tests, physical exam, spectroscopy, and laboratory test (urine test).
Get Sample Copy of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8197
Increase in geriatric population, surge in incidence of cancer, rise in technological advancements in imaging equipment, and shift in preference toward non-invasive cancer diagnosis techniques are the major factors propelling the global market. According to the World Health Organization (WHO), the global population aged 60 years or above stood at 1 billion in 2020 and is anticipated to reach 1.4 billion by 2030 and 2.1 billion by 2050. Thus, the population of people aged 60 years and older will double by 2050 compared to that in 2020. Furthermore, the number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million by 2050. This geriatric population is more prone to chronic diseases such as cancer. This is projected to boost the demand for cancer diagnosis. In turn, this is anticipated to augment the global non-invasive cancer diagnostics market size from 2022 to 2031. According to statistics published by the Global Cancer Observatory, the number of new cancer cases across the world stood at 19,292,789 in 2020.
COVID-19 Impact on Global Non-invasive Cancer Diagnostics Market
COVID-19 had a negative effect on the non-invasive cancer diagnostics market in 2020. The unprecedented outbreak of the COVID-19 pandemic largely affected countries in North America and Europe such as the U.S., Italy, Spain, the U.K., France, and Germany. Implementation of lockdowns due to COVID-19 outbreak delayed the diagnosis of cancer. It also affected the logistics and supply of cancer diagnosis equipment or products. Nationwide lockdowns, government regulations, and increase in infection rate across countries created a widespread financial impact on cancer hospitals and outpatient centers. Several hospitals and clinics witnessed a drop in number of patient visits amid COVID-19, ultimately reducing client contact. Furthermore, several cancer diagnostic procedures and non-invasive cancer treatments were delayed due to the pandemic. Limited availability of healthcare staff was another factor that restrained the cancer diagnostics market.
Easy to Perform and Lower Cost Features Propelling Imaging Test Segment
In terms of test type, the imaging test segment held the largest global non-invasive cancer diagnostics market share in 2021. The trend is expected to continue during the forecast period due to the increase in patient preference for imaging tests. Ultrasound, Magnetic Resonance Imaging (MRI), Computerized Tomography (CT), mammography, Positron Emission Tomography (PET), X-ray/mammography, and liquid biopsy are non-invasive diagnostic tests for cancer detection. These tests are simpler and less expensive than blood or plasma tests. Hence, increasing number of cancer patients are opting for painless imaging tests to diagnose and monitor cancer progression.
The urine test segment is likely to dominate the global non-invasive cancer diagnostics market during the forecast period owing to the rise in adoption of the urinalysis test to check for traces of blood, bacteria, or abnormal cells in the urine in cancer or bladder cancer diagnosis cases.
Surge in Incidence of Breast Cancer across Globe
Based on cancer type, the breast cancer segment held substantial share of the global market in 2021. This can be ascribed to the surge in incidence of breast cancer across the globe and increase in population of women aged 50 to 74. Rise in initiatives by various organizations for early screening and diagnosis of breast cancer is projected to augment the segment in the next few years. According to the Global Cancer Observatory, 2,261,419 breast cancer cases were reported across the world in 2020.
Lung cancer is projected to be a lucrative segment of the global market during the forecast period, as it is the leading cancer in the U.S. and across the globe. According to the Centers for Disease Control and Prevention (CDC), cigarette smoking is linked to about 80% to 90% of lung cancer deaths in the U.S. Rise in usage of chest X-ray, CT, MRI, PET, and bone scans for lung cancer diagnosis is likely to propel the lung cancer segment from 2022 to 2031.
Enquiry before Buying @ https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=8197
Rise in Non-invasive Cancer Diagnostic Procedures Driving Hospitals & Clinics Segment
In terms of end-user, the hospitals & clinics segment held the largest share of the global market in 2021. This can be ascribed to the increase in number of hospitals and rise in non-invasive cancer diagnostic procedures in this setting. According to the American Hospital Association (AHA), the number of hospitals in the U.S. rose from 5,564 in 2017 to 6,093 in 2022. Increase in number of hospitals in the region has led to a surge in number of cancer diagnosis tests performed.
Regional Analysis of Non-Invasive Cancer Diagnostics Market
According to the global non-invasive cancer diagnostics market analysis, North America accounted for significant share of the market in 2021. This can be ascribed to changing demographics, evolving lifestyle, increase in incidence of cancer, and presence of well-established point-of-care diagnostic centers in the U.S. and Canada. For instance, the number of new cancer cases in North America stood at 2,556,862 in 2020.
The market in Asia Pacific is expected to grow at a rapid pace during the forecast period. Increase in geriatric population, surge in incidence of cancer, and rise in awareness about non-invasive equipment for cancer diagnosis are expected to augment the market in the region during the forecast period. Governments of Japan, China, and India fund and support universities and research institutes in order to develop new technologies for cancer diagnosis. This is driving the market for non-invasive cancer diagnostics in the region.
Analysis of Key Players in Global Non-invasive Cancer Diagnostics Market
The non-invasive cancer diagnostics market report concludes with the company profiles section that includes key information about the major players in the global non-invasive cancer diagnostics market. Market participants are focusing on strategies such as new product or solution offerings, mergers, and partnerships & collaborations to compete in the global market. The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Beverly Hills Cancer Center, SimonMed Imaging, RadNet Management, Inc., RAYUS Radiology (Diagnostic Services Holdings, Inc.), Unilabs AB, Sonic Healthcare Limited, and Dr Lal PathLabs Ltd. are the prominent players operating in the global market.
Key Developments in Global Non-Invasive Cancer Diagnostics Market
- In October 2022, RadNet, Inc.’s joint venture, New Jersey Imaging Network (NJIN), acquired the outpatient radiology assets of Montclair Radiology, the owner of six imaging centers in northern New Jersey. Through this move, RadNet aims to strengthen its position as a provider of outpatient imaging in northern and central New Jersey. It aims to offer high-quality, lower cost, and convenient services as an alternative to more expensive hospital-based imaging.
- In July 2022, Unilabs Sweden partnered with Subtle Medical, a healthcare technology company using artificial intelligence for faster and higher quality MRI, to improve the quality and efficiency of their MRI imaging. Subtle Medical’s SubtleMR would assist radiologists in performing high-quality imaging more efficiently. SubtleMR is an AI-powered software that improves image quality from upward of 60% faster scan times. The software has been clinically validated in multiple peer-reviewed journals, showing clinical quality and integrity across diverse sites, scanners, and patients.
Each of these players has been profiled in the non-invasive cancer diagnostics market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
About Us
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.
Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.
Contact Us:
Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
